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Is the halo always holy? Glucocorticoid impact on
detecting cranial large-vessel arteritis
The importance of temporal artery biopsy
In the developed world, GCA is the most common inflam-
matory vasculitis and may cause major morbidities, of
which blindness is the most feared. Early diagnosis via
temporal artery biopsy (TAB) and glucocorticoid treatment
are still gold standard recommendations [1], but several
issues may complicate this in real-life practice. First, TAB
may be falsely negative due to skip lesions or inadequate
material, truly negative in non-cranial large-vessel vascu-
litis (LVV) [2] or simply refused by the patient. Secondly,
prior glucocorticoid exposure will influence the histo-
logical findings. This is particularly relevant in cases of
proven and treated GCA with a suspected relapse. The
development of non-invasive imaging techniques such as
ultrasonography, MRI and PET has generated a large
amount of data but has not eliminated the need for TAB,
despite initial enthusiasm that it would [3]. However, as
adjunct investigations in cases of high pre-test probability
but negative TAB, all or one of these diagnostic tech-
niques may be very informative. Although high-resolution
MRI and colour-coded duplex sonography (CCDS) com-
pare well in terms of sensitivity and specificity [4], neither
has been prospectively compared with TAB [1]. Although
it is clear that mural inflammatory changes resolve under
glucocorticoid therapy, the extent and timing of this reso-
lution varies. In classic cases of GCA, glucocorticoid treat-
ment should commence immediately and a biopsy should
be performed as soon as possible, ideally within 12
weeks [5]. However, biopsies may still remain positive
up to 6 weeks after glucocorticoid exposure [6, 7]. We
are also unclear how quickly glucocorticoid exposure
eliminates MRI and CCDS signs, with some authors sug-
gesting that there is no change for at least 1 week and that
they can persist for up to 2 months after treatment begins
[3, 8].
In this edition of Rheumatology, Hauenstein et al.’s
retrospective study assesses the impact of prior gluco-
corticoid treatment on the ability of high-resolution MRI
and CCDS to demonstrate mural inflammation of the cra-
nial arteries in GCA. They found that within just a few
days, the ability of both techniques to detect mural inflam-
mation is markedly reduced [9].
Using ACR criteria, Hauenstein et al. identified 59 pa-
tients with possible GCA who had undergone both CCDS
and MRI within 10 days of diagnosis. All patients had
received glucocorticoids for <2 weeks. In the initial
study population of 59 patients suspected of having
GCA, the final diagnosis was only reached by the
rheumatologist at a follow-up visit of 56 months. This
reduced the number of confirmed GCA cases to 36. Of
these, 24 had positive TAB and 4 had false negative biop-
sies considered to be the result of skip lesions. The
excluded 23 patients were used as controls in the
analysis.
In the diagnosed patients, both CCDS (88%) and MRI
(85%) performed well with regard to sensitivity at 1 day
after glucocorticoid exposure. Both reduced rapidly to 50
and 56%, respectively, at >4 days after exposure.
However, specificity remained high. When TAB was
used as the reference point, the initial sensitivity was
even higher: 92% for CCDS and 90% for MRI, remaining
high at >4 days after exposure for MRI (90%) but drop-
ping off for CCDS (50%). Specificity also remained high
for MRI at 4 days (80%), but was reduced for CCDS (50%)
due to more false positive results.
Hauenstein et al. conclude that while both CCDS and
MRI have high sensitivity in detecting mural oedema in the
first few days of glucocorticoid exposure in true GCA
cases, this rapidly declines thereafter. The obvious limita-
tions of this paper are its retrospective nature and rather
small number of patients eventually entering the study.
Additionally, it is assumed that all true GCA cases were
confirmed, although this is uncertain without a positive
TAB. However, the data do not contradict other prospect-
ive studies suggesting that both CCDS and MRI may
remain positive for many weeks, since the specificity of
both techniques was shown to be high.
As the authors rightly point out, studies of non-cranial
LVV have shown the persistently high sensitivity of both
techniques [10, 11] after glucocorticoid exposure, prob-
ably reflecting the larger mass of oedematous vessel wall.
Also, as all those working in the field appreciate, the diag-
nosis of relapse in proven GCA cases during glucocorti-
coid therapy remains a major challenge. As yet, there are
no scientific studies evaluating the performance of either
CCDS or MRI in this situation.
In summary, while both CCDS and MRI offer attractive
non-invasive options for assessing cranial arteries in sus-
pected GCA, neither has yet replaced TAB, which is still
recommended in all cases. Additionally, the application of
glucocorticoids in patients strongly suspected of having
GCA should not wait for either a TAB or non-invasive
examinations, which should be performed as soon as
possible and certainly within 12 weeks. Finally, it is
never too late to perform these investigations in unclear
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cases, remembering that although sensitivity may be lost,
specificity is usually retained.
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